is aventurine jade real jade
The Spotlight Series highlights the Marquis resumes and career accomplishments of hand-selected professionals UNIONDALE, N.Y. , Dec. 2, 2024 /PRNewswire/ -- Marquis Who's Who (MWW), the world's leading biographical publisher, is proud to recognize Spotlight biographees for the fourth quarter of 2024. The Spotlight Series shines a light on a select group of individuals to share their unique bodies of work through exposure on the MWW corporate home page and the official Spotlight website . Spotlight listees exhibit qualities that complement the MWW motto: "Often imitated, never duplicated." These exemplary professionals hold influence, status and proficiency within their fields that mark them as respected and trusted experts. It is Marquis' great honor to celebrate these individuals' accomplishments and highlight their work, influence and impact. Each month, distinguished MWW listees are selected for positions in the Spotlight Series. Listees' Marquis features are carefully curated to share in a convenient location online. These features include highlights, such as Marquis-issued awards and narratives in one of many print or online publications. Each Spotlight feature is introduced by a biography, which provides a snapshot of a listee's career highlights, philanthropic endeavors, and/or career achievements. The Marquis Spotlight Series recognized 15 prominent listees in the fourth quarter of 2024: October 2024 Dr. Lin Morel Founder and Chief Executive Officer Beyond Words Group Inc. Joanne Fern Owner J&S Operated Equipment Rentals Harry H. Kazakian Founder, President and Chief Executive Officer USA Express Legal & Investigative Services Inc. Dr. Joseph G. R. Martinez Regents' Professor (Retired) University of New Mexico Dr. Floyd W. McCoy Professor Emeritus University of Hawaii -Windward November 2024 Jillian C. Bergeron Master Aesthetician and Holistic Healer Dr. Gordon E. MacKinnon Licensed Clinical Psychologist and Educator MacKinnon Psychological Associates Michael Ettinger, Esq. President Ettinger Law Firm James R. Eigenberg County Commissioner Jackson County, Minnesota Victor M. Renteria Secondary School Educator Bowie High School December 2024 Dr. Douglas C. Munski Professor University of North Dakota Dr. Imogene Mathison Mixson Academic Dean (Retired) Wallace State Community College Lea-Ann M. Riddell, RN Manager of Resident Care Steeves & Rozema Dr. Richard Ferrell Associate Professor of Psychiatry Geisel School of Medicine, Dartmouth College Michael Garvich Senior Product Care Engineer Team Leader Electrolux North America Congratulations to these Spotlight listees, who are pillars of the Marquis Who's Who community and examples of the highest standard in their fields and among their professional networks. About Marquis Who's Who ® Since 1899, when A. N. Marquis printed the first edition of Who's Who in America ® , Marquis Who's Who ® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion, and entertainment. Today, Who's Who in America ® remains an essential biographical source for thousands of researchers, journalists, librarians, and executive search firms around the world. Marquis ® publications may be visited via the official Marquis Who's Who ® website at www.marquiswhoswho.com . SOURCE Marquis Who's WhoJoe Burrow is no longer talking about the playoffs after another loss by the high-scoring Bengals
Arsenal delivered the statement Champions League win Mikel Arteta had demanded as they swept aside Sporting Lisbon 5-1. Arteta wanted his team to prove their European credentials following some underwhelming displays away from home, and the Gunners manager got exactly what he asked for. Goals from Gabriel Martinelli, Kai Havertz, Gabriel Magalhaes, Bukayo Saka and Leandro Trossard got their continental campaign back on track in style following the 1-0 defeat at Inter Milan last time out. A memorable victory also ended Sporting’s unbeaten start to the season, a streak of 17 wins and one draw, the vast majority of which prompted Manchester United to prise away head coach Ruben Amorim. The Gunners had failed to win or score in their two away games in the competition so far this season, but they made a blistering start in the Portuguese capital and took the lead after only seven minutes. Declan Rice fed overlapping full-back Jurrien Timber, who curled a low cross in behind the home defence for Martinelli to finish at the far post. Arsenal doubled their lead in the 20th minute thanks to a glorious ball over the top from Thomas Partey. Saka escaped the clutches of his marker Maximiliano Araujo to beat the offside trap and poke the ball past advancing goalkeeper Franco Israel for Havertz to tap home. It was a scintillating first-half display which completely overshadowed the presence of Viktor Gyokeres in Sporting’s attack. The prolific Sweden striker, formerly of Coventry, has been turning the heads of Europe’s top clubs with his 24 goals in 17 games this season – including a hat-trick against Manchester City earlier this month. But the only time he got a sniff of a run at goal after an optimistic long ball, he was marshalled out of harm’s way by Gabriel. David Raya was forced into one save, tipping a fierce Geovany Quenda drive over the crossbar. But Arsenal added a third on the stroke of half-time, Gabriel charging in to head Rice’s corner into the back of the net. To rub salt in the wound, the Brazilian defender mimicked Gyokeres’ hands-over-his-face goal celebration. That may have wound Sporting up as they came out after the interval meaning business, and they pulled one back after Raya tipped Hidemasa Morita’s shot behind, with Goncalo Inacio netting at the near post from the corner. Former Tottenham winger Marcus Edwards fired over, as did Gyokeres, with Arsenal temporarily on the back foot. But when Martin Odegaard’s darting run into the area was halted by Ousmane Diomande’s foul, Saka tucked away the penalty. Substitute Trossard added the fifth with eight minutes remaining, heading in the rebound after Mikel Merino’s shot was saved, and Gyokeres’ miserable night was summed up when his late shot crashed back off the post.
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE AmgenUniversity of Phoenix Supports Arizona Diamondbacks® Annual Winter Classic CelebrationKim Kardashian seen looking dazed and confused crawling on floor in new music video